HRTS
Tema Heart & Health ETF
HRTS seeks to provide investors with exposure to companies that are focused on developing treatments and solutions for obesity and cardiometabolic conditions.
US
EQUITY
Active
MANAGEMENT STYLE
$ 52.1 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Inception date | Nov 20, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 10.6 % |
| UNITEDHEALTH GROUP INC | 5.5 % |
| NOVO NORDISK A/S-B | 5.4 % |
| ROCHE HOLDINGS LTD-SPONS ADR | 4.5 % |
| MERCK & CO. INC. | 4.1 % |
| ASTRAZENECA PLC | 4.0 % |
| JOHNSON & JOHNSON | 3.7 % |
| THERMO FISHER SCIENTIFIC INC | 3.6 % |
| GILEAD SCIENCES INC | 3.4 % |
| NOVARTIS AG | 3.4 % |
Constituent Breakdown
| Number of holdings | 42 |
| Herfindahl-Hirschman Index | 368 |
| Wgt avg mkt cap (mns) | $254,048 |
| Large cap (>$10bn) | 92.0% |
| Mid cap ($2-10bn) | 6.5% |
| Small cap (<$2bn) | 0.3% |
| Developed mkts. | 97.2% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 73.3 % |
 |
SWITZERLAND | 7.8 % |
 |
DENMARK | 6.8 % |
 |
BRITAIN | 4.0 % |
 |
ISRAEL | 2.0 % |
 |
IRELAND | 2.0 % |
 |
JAPAN | 1.4 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -4.6% | 15.3% | 3.8% | -- | -- | -- | -- | 10.1% |
| Dividend Yield | 0.0% | 1.6% | 1.5% | -- | -- | -- | -- | 1.3% |
| Total Returns | -4.6% | 16.9% | 5.2% | -- | -- | -- | -- | 11.4% | Ann. Volatility | 17.2% | 17.3% | 18.9% | -- | -- | -- | -- | 19.2% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.67 | 23% |
| MSCI EAFE | 0.71 | 35% |
| MSCI Emg Mkts | 0.39 | 17% |
Liquidity Measures
| Avg. volume (000) | 4 |
| ADV traded (mns) | $0 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.31% |
Technical Indicators
| 30d moving avg. (EMA) | $33.77 |
| Relative strength (RSI) | 52 |
| MACD/Signal | 0.04/-0.05 |
| Bollinger Bands (Upper/Lower) | $34.31/$32.84 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HRTS |
Expenses vs. HRTS |
ALTAR Score™ vs. HRTS |
|---|---|---|---|---|
| IXJ | iShares Global Healthcare ETF | 54.3% | -33 bp | +3.6% |
| XLV | Health Care Select Sector SPDR | 52.4% | -67 bp | +3.8% |
| FHLC | Fidelity MSCI Health Care Index ETF | 52.2% | -67 bp | +2.5% |
| IYH | iShares U.S. Healthcare ETF | 52.1% | -35 bp | +3.1% |
| VHT | Vanguard Health Care ETF | 51.7% | -66 bp | +2.3% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 40.4% | 0 bp | -1.8% |
| HART | IQ Healthy Hearts ETF | 36.9% | -30 bp | +2.9% |
| CANC | Tema Oncology ETF | 36.0% | 0 bp | -5.3% |
| BMED | Future Health ETF | 34.3% | +10 bp | -2.3% |
| AGNG | Global X Aging Population ETF | 32.9% | -25 bp | +1.5% |
Risk and Returns: HRTS vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/29/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
3.3%
ALTAR SCORE™
17th
PERCENTILE
AVOID
ETFRC RATING
There are 1,401 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. HRTS's ALTAR Score™ is approximately -1.0 standard
deviations above the category average. This places HRTS in the 17th percentile
among funds in the category.
Sell-Side Consensus
$41.03
PRICE TARGET
+18.9%
UPSIDE